Novel 1,3,4-oxadiazole Targets STAT3 Signaling to Induce Antitumor Effect in Lung Cancer

Area of Science:

• Oncology
• Medicinal Chemistry

Background:

• Lung cancer is a leading cause of cancer mortality globally.
• Signal transducer and activator of transcription 3 (STAT3) is a key oncogenic factor frequently activated in lung cancer.

Purpose of the Study:

• To synthesize and evaluate novel oxadiazole conjugated indazoles for anticancer activity.
• To investigate the mechanism of action of the most potent compound, CHK9, focusing on STAT3 inhibition.

Main Methods:

• Synthesis of novel oxadiazole conjugated indazoles.
• In vitro cytotoxicity assays (IC50 determination) against lung cancer cell lines.
• Apoptosis assays (Annexin-FITC, TUNEL assay).
• Western blot analysis to assess protein expression and phosphorylation (STAT3, JAK2, STAT5, apoptosis-related proteins).
• STAT3-dependent luciferase reporter gene assay.
• In vivo studies using a murine lung cancer model and normal murine model.

Main Results:

• Compound CHK9 demonstrated significant cytotoxicity against lung cancer cells (IC50: 4.8-5.1 µM).
• CHK9 induced apoptosis and dose-dependently reduced STAT3 phosphorylation (pSTAT3Y705) without affecting JAK2 or STAT5.
• CHK9 suppressed STAT3 transcriptional activity, modulated pro- and anti-apoptotic protein expression, and reduced tumor burden in vivo with minimal toxicity.

Conclusions:

• CHK9 is a promising novel agent that inhibits lung cancer cell and tumor growth.
• The anticancer effects of CHK9 are mediated through the suppression of the STAT3 signaling pathway.
• CHK9 warrants further investigation as a potential therapeutic candidate for lung cancer treatment.